Considering the likely necessity of combination therapies for AML treatment,47 we evaluated the efficacy of ZW27941 in combination with cytarabine (Ara-C) and BCL-2 inhibitor venetoclax. The gene discussed is BCL2; the disease is acute myeloid leukemia.